安罗替尼联合放射性碘治疗甲状腺乳头状癌头皮转移的疗效：一例病例报告及文献复习
Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature.
作者信息
Zhang Li-Yong, Cai Shao-Jun, Liang Bo-Yan, Yan Shou-Yi, Wang Bo, Li Meng-Yao, Zhao Wen-Xin
机构信息
Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
出版信息
World J Clin Cases. 2023 Apr 26;11(12):2839-2847. doi: 10.12998/wjcc.v11.i12.2839.
BACKGROUND
Papillary thyroid cancer (PTC) is one of the well-differentiated thyroid tumors. Cutaneous metastasis from differentiated thyroid cancers occurs in < 1% of primary thyroid carcinomas but produces the worst survival prognosis. The multi-targeting tyrosine kinase inhibitor anlotinib has been approved to treat refractory advanced non-small-cell lung cancer as well as advanced soft-tissue and clear cell sarcomas in China.
CASE SUMMARY
In a patient with scalp metastasis caused by PTC, thyroid and skull metastasis tumor sizes were significantly reduced after a trial of neoadjuvant anlotinib therapy for 3 cycles. Anlotinib maintenance medication after thyroidectomy further reduced the metastatic skull tumor size thereby preventing the requirement for craniotomy.
CONCLUSION
The outcome of the present trial confirmed the potential of anlotinib therapy to treat scalp metastasis induced by PTC and point the way for the treatment of similar diseases in the future.
背景
乳头状甲状腺癌（PTC）是一种分化良好的甲状腺肿瘤。分化型甲状腺癌的皮肤转移在原发性甲状腺癌中发生率<1%，但预后最差。多靶点酪氨酸激酶抑制剂安罗替尼在中国已被批准用于治疗难治性晚期非小细胞肺癌以及晚期软组织和透明细胞肉瘤。
病例摘要
一名由PTC引起头皮转移的患者，在新辅助使用安罗替尼治疗3个周期后，甲状腺和颅骨转移瘤大小显著缩小。甲状腺切除术后安罗替尼维持治疗进一步缩小了颅骨转移瘤的大小，从而避免了开颅手术的需要。
结论
本试验结果证实了安罗替尼治疗PTC引起的头皮转移的潜力，并为未来类似疾病的治疗指明了方向。
Zotero 插件